SLC5A2 and atrial fibrillation: This cohort study compares the incidence of atrial fibrillation in patients with type 2 diabetes associated with use of sodium-glucose cotransporter-2 inhibitors with dipeptidyl peptidase-4 inhibitors or glucagonlike peptide-1 receptor agonists.